EP1586328A4 - Wirkstoff zur erhöhung der lebenserwartung bei der therapie bösartiger tumore - Google Patents

Wirkstoff zur erhöhung der lebenserwartung bei der therapie bösartiger tumore

Info

Publication number
EP1586328A4
EP1586328A4 EP03768290A EP03768290A EP1586328A4 EP 1586328 A4 EP1586328 A4 EP 1586328A4 EP 03768290 A EP03768290 A EP 03768290A EP 03768290 A EP03768290 A EP 03768290A EP 1586328 A4 EP1586328 A4 EP 1586328A4
Authority
EP
European Patent Office
Prior art keywords
agent
treatment
malignant tumor
life expectancy
improving life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03768290A
Other languages
English (en)
French (fr)
Other versions
EP1586328A1 (de
EP1586328B1 (de
Inventor
Kenji Okajima
Fujio Matsuo
Hiroyuki Sutoh
Yoichi Ogata
Tomohiro Nakagaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of EP1586328A1 publication Critical patent/EP1586328A1/de
Publication of EP1586328A4 publication Critical patent/EP1586328A4/de
Application granted granted Critical
Publication of EP1586328B1 publication Critical patent/EP1586328B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03768290A 2002-12-27 2003-12-26 Wirkstoff zur erhöhung der lebenserwartung bei der therapie bösartiger tumore Expired - Lifetime EP1586328B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002379409 2002-12-27
JP2002379409 2002-12-27
JP2003129208 2003-05-07
JP2003129208 2003-05-07
PCT/JP2003/016858 WO2004060395A1 (ja) 2002-12-27 2003-12-26 悪性腫瘍治療における生命予後の改善剤

Publications (3)

Publication Number Publication Date
EP1586328A1 EP1586328A1 (de) 2005-10-19
EP1586328A4 true EP1586328A4 (de) 2009-08-05
EP1586328B1 EP1586328B1 (de) 2013-02-20

Family

ID=32716312

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03768290A Expired - Lifetime EP1586328B1 (de) 2002-12-27 2003-12-26 Wirkstoff zur erhöhung der lebenserwartung bei der therapie bösartiger tumore

Country Status (6)

Country Link
US (3) US20060094650A1 (de)
EP (1) EP1586328B1 (de)
JP (1) JPWO2004060395A1 (de)
AU (1) AU2003292840A1 (de)
ES (1) ES2400853T3 (de)
WO (1) WO2004060395A1 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0191606A2 (de) * 1985-02-08 1986-08-20 Eli Lilly And Company Vektoren und Verfahren zur Expression einer die Aktivität des menschlichen Proteins-C enthaltenden Substanz

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0191606A2 (de) * 1985-02-08 1986-08-20 Eli Lilly And Company Vektoren und Verfahren zur Expression einer die Aktivität des menschlichen Proteins-C enthaltenden Substanz

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMIRKHOSRAVI ALI ET AL: "Activated protein C inhibits tumor cell-induced coagulation activation in vivo and suppresses experimental lung metastasis.", BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 14a, XP009118980, ISSN: 0006-4971 *
GOUIN-THIBAULT I ET AL: "The thrombophilic state in cancer patients", ACTA HAEMATOLOGICA (BASEL), vol. 106, no. 1-2, September 2001 (2001-09-01), pages 33 - 42, XP009118954, ISSN: 0001-5792 *
JOYCE DAVID ET AL: "IMPROVEMENT OF DISSEMINATED INTRAVASCULAR COAGULATION IN SEVERE SEPSIS PATIENTS TREATED WITH RECOMBINANT HUMAN ACTIVATED PROTEIN C" and "DISSEMINATED INTRAVASCULAR COAGULATION IN SEVERE SEPSIS PATIENTS TREATED WITH RECOMBINANT HUMAN ACTIVATED PROTEIN C, A RETROSPECTIVE SUBGROUP ANALYSIS", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 11 PART 1, 11 December 2001 (2001-12-11), pages 445A (ABSTRACT1865 AND ABSTRACT1866), XP008075901, ISSN: 0006-4971 *
See also references of WO2004060395A1 *
WADA H ET AL: "THROMBOMODULIN INHIBITS TISSUE FACTOR-INDUCED THROMBIN GENERATION IN PLASMA OF PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 11, PART 2, 1 January 2001 (2001-01-01), pages 78B,ABSTR.NO.#3937, XP003021736, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
ES2400853T3 (es) 2013-04-12
WO2004060395A1 (ja) 2004-07-22
AU2003292840A1 (en) 2004-07-29
US20100120693A1 (en) 2010-05-13
US20060094650A1 (en) 2006-05-04
EP1586328A1 (de) 2005-10-19
US20080182791A1 (en) 2008-07-31
EP1586328B1 (de) 2013-02-20
JPWO2004060395A1 (ja) 2006-05-11

Similar Documents

Publication Publication Date Title
EP1411880A4 (de) Rekombinante vsv zur behandlung von tumorzellen
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1311262A4 (de) Krebstherapie durch kombinationstherapie
EP1810034A4 (de) Prädiktive marker in der krebstherapie
EP1535610A4 (de) Therapeutisches krebsmittel
EP1392818A4 (de) Zur behandlung von krebserkrankungen beim menschen geeigneter chimärer immunrezeptor
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
EP1501489A4 (de) Kombinationstherapie zur behandlung von krebs
NO20034877L (no) Anvendelse av bifosfonater ved behandling av benmetastase forbundet med prostatakreft
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
EP1465854A4 (de) Chalconderivate und deren verwendung zur behandlung von krankheiten
NO20024273L (no) Terapeutiske anvendelser av PPAR-mediatorer
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
FI20000863A0 (fi) Uusi hoitomenetelmä
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
EP1572093A4 (de) Verbesserte behandlung von krebs mit glutamin
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
EP1320376A4 (de) Behandlung von prostatakrebs
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1776136A4 (de) Behandlung von entmyelinisierenden erkrankungen
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
NO20022245D0 (no) Onkolyttiske kombinasjoner for behandling av cancer
IS6137A (is) Meðhöndlun á hugsýkistruflunum
DK1553950T3 (da) Terapeutisk behandling

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090707

17Q First examination report despatched

Effective date: 20091026

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 597234

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2400853

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130412

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60343322

Country of ref document: DE

Effective date: 20130418

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130520

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130620

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130521

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

26N No opposition filed

Effective date: 20131121

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60343322

Country of ref document: DE

Effective date: 20131121

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20131226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131226

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131226

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20141117

Year of fee payment: 12

Ref country code: FR

Payment date: 20141118

Year of fee payment: 12

Ref country code: CH

Payment date: 20141215

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20141222

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150130

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20031226

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60343322

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 597234

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151226

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160701

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151226

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20170126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151227